ImmuSAFE Biochip


lmmuSAFE™ is a novel, lab-based biochip test for COVID-19 that enables highly quantitative determination of both the level and target location of SARS-CoV-2 antibodies in an individual. The tests answer 4 fundamental questions:

Scenario 1 – suspected COVID-19 positive individual

1. Confirming with high accuracy whether an individual has been infected with the virus that causes COVID-19.
2. Determine whether the level and target location of the antibodies in an individual are likely to offer protectivity.

Scenario 2 – following COVID-19 vaccination

3. Confirming that an individual has generated a sufficiently strong immune response to the vaccine to confer protection.
4. Retesting to confirm the status of ongoing protection and evaluating whether a booster vaccine is required.

lmmuSAFE™ utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. Multiple domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.

The biochip enables the determination of the target epitopes, titres and immunoglobulin class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. lmmuSAFE™ can also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.

Key Applications

ImmuSAFE™ can be utilised for vaccine clinical trials or sero-prevalence research studies. 

Population antibody profiling for sero-prevalence research

The target epitope of antibodies produced following infection exhibit a significant level of diversity across a population. ImmuSAFE™ provides a more accurate determination of sero-prevalence by targeting multiple domains of SARS-CoV-2 proteins.

Determine the protective quality and quantity of antibodies produced

Some individuals produce antibodies that target locations which are neutralising (protective), whereas others produce non-neutralising antibodies. ImmuSAFE™ can be used to identify individuals who have high titres of potentially neutralising antibodies against SARS-CoV-2.

Enable quantitative assessment of antigen-specific response by individuals in vaccine trials

Investigate SARS-CoV-2 specific immunoreactivity in patients and healthy individuals for vaccine development, safety and efficacy determination in clinical trials.

As shown below, data from ImmuSAFE™ tests enable 3 major conclusions to be inferred:

  1. There is a wide variation in antibody titres across SARS-CoV-2 infected individuals
  2. There is a high degree of variation in patient-specific antibody responses to the different domains of SARS-CoV-2 proteins
  3. Wider coverage of target epitopes leads to increased sensitivity and specificity

Relative IgG titres in convalescent COVID-19 patient and healthy sera against different domains of SARS-CoV-2 nucleocapsid [For illustration purposes only].

Product Description

The ImmuSAFE™ product range also includes other biochip-based tests that incorporate additional viral antigens. Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.

Code Product Description Links
39508H ImmuSAFE™ COVID+ Protein Microarray
Contains multiple SARS-CoV-2 specific domains (Nucleocapsid and Spike proteins) including full-length and numerous truncated versions. Key applications are vaccine clinical trials and sero-prevalence research studies.
Read More
39508V ImmuSAFE™ Respiratory Virus Protein Microarray
Contains multiple SARS-CoV-2 proteins, Nucleocapsid proteins from 5 other human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Key application is sero-prevalence research studies.
39508R ImmuSAFE™ Discovery Virus Protein Microarray
Contains multiple SARS-CoV-2 proteins, Nucleocapsid proteins from 13 other Coronaviruses including 5 human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Key application is for research and development purposes.
COVID-19 Antigens
All antigens are expressed in sf9 insect cells using the patented KREX functional proteomics technology. Viral antigens are full-length, correctly folded, functional, with both conformational and non-conformational antibody binding sites preserved. Each antigen is supplied as either lysate or purified protein.
Read More


IMMUNOME Protein Array

High-throughput autoantibody screening protein array containing 1600+ autoantigens


Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza viruses

SEROMAX Blood Collection Kit

Obviates conventional blood draw and cold chain by only requiring a pin-prick of blood

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361